Twilight Litaka Pharma Limited
Regd. Office : B-22, 'H' BLOCK, MIDC PIMPRI, PUNE-411018

PART I

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DEC, 2012

(Rs.in Lac)

S No.	Particulars	Quarter Ended			Year to Date		Previous Year ended
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		31.12.2012	30.09.2012	31.12.2011	31.12.2012	31.12.2011	31.03.2012
1	a. Net Sales / Income From Operations	5586.63	8995.17	18672.48	**30615.42**	55093.62	73018.65
	b. Other Operating Income			-		-	
2	Expenditure						
	a Increase/decrease in stock in trade & WIP	188.83	304.38	23.17	**542.99**	-140.16	-276.52
	b Consumption of Raw material	2493.87	4014.01	13515.24	**14225.11**	38550.68	40054.81
	c Purchase of traded goods	1851.97	2982.13	536.95	**9725.36**	3471.36	16402.58
	d Employee cost	158.10	254.85	538.05	**866.71**	1529.61	1998.63
	e Depreciation	128.88	132.63	133.48	**397.47**	382.57	510.51
	f Other expenditure	501.12	896.46	1240.54	**2465.57**	3437.22	7983.53
	g Expenditure (a to f)	**5322.77**	8584.46	15987.43	**28223.21**	47231.28	66673.54
3	**Profit from Operations before Other Income, Interest and Exceptional Items (1-2)**	**263.86**	410.71	2685.05	**2392.21**	7862.34	6345.11
4	Other Income	10.24	13.56	13.88	**44.09**	77.49	104.40
5	**Profit before Interest & Exceptional Items (3+4)**	**274.10**	424.27	2698.93	**2436.30**	7939.83	6449.51
6	Interest	**1013.27**	1006.68	1283.84	**3469.08**	3466.17	4502.39
7	**Profit/(Loss) after Interest, but before Exceptional Items (5-6)**	**(739.17)**	(582.41)	1415.09	**(1,032.78)**	4473.66	1947.12
8	Exceptional Items	-	-	-	-	-	(1,503.07)
9	**Profit/(Loss) from Ordinary Activities before tax (7+8)**	**(739.17)**	(582.41)	1415.09	**(1,032.78)**	4473.66	444.05
10	Tax Expenses	**0.00**	0.00	477.00	**0.00**	1270.00	92.00
11	**Profit/(Loss) from Ordinary Activities after tax (9-10)**	**(739.17)**	(582.41)	938.09	**(1,032.78)**	3203.66	352.05
12	Extraordinary items (net of tax expense)	-	-	-	-	-	-
13	**Net Profit/(Loss) for the period**	**(739.17)**	(582.41)	938.09	**(1,032.78)**	3203.66	352.05
14	Paid-up Equity Share Capital (Equity share of Rs.5/- each)	**1239.06**	1239.06	1239.06	1239.06	1239.06	1239.06
15	Reserve excluding revaluation reserves	**18394.26**	19058.43	18837.86	**18394.26**	18837.86	19427.04
16	Earning per share (EPS)						
	a. Basic and diluted EPS before extraordinary items for the period	(2.98)	(2.35)	*3.74	(4.17)	*13.44	*1.42
	b. Basic and diluted EPS after extraordinary items for the period.	(2.98)	(2.35)	*3.74	(4.17)	*13.44	*1.42
II	**INFORMATION FOR THE QUARTER AND SIX MONTHS ENDED 31.12.2012**						
A	**PARTICULARS OF SHAREHOLDING**						
1	Aggregate of non promoter shareholding						
	number of shares	23683261	23683261	23225796	23683261	23225796	23520796
	percentage of shareholding	95.57	95.57	93.72	95.57	93.72	94.91
2	Promoters and Promoters Group shareholding						
	a) Pledged / Encumbered						
	- Number of shares	796938	796938	1531247	796938	1531247	1236247
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	72.58	72.58	98.44	72.58	98.44	98.07
	- Percentage of shares (as % to the total share capital of the Company)	3.22	3.22	6.18	3.22	6.18	4.99
	b) Non Encumbered						
	- Number of shares	301086	301086	24242.00	301086	24242.00	24242
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	27.42	27.42	1.56	27.42	1.56	1.93
	- Percentage of shares (as % to the total share capital of the Company)	1.21	1.21	0.10	1.21	0.10	0.10

* not annualised

Particulars	3 months ended 31/12/2012
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	17
Received during the quarter	3
Disposed of during the quarter	19
Remaining unresolved at the end of the quarter	1

Notes :

1] The above unaudited results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th February, 2013.

2] The Company is primarily engaged in Pharmaceutical formulations business, which in the context of Accounting Standard (AS17) "'Segment Reporting" is considered to be the only business segment.

3] The financial results for the quarter and half year ended on 31st December,2012 of the company are prepared on standalone basis.

4] The Companies Bank accounts became NPA and consequently some of the banks have issued notices under SARFAISI ACT 2002 and also filed suits in DRT. Some of the creditors of the company have filed windig up petitions.

5] The above results were subject to Limited Review by the Statutory Auditors of the Company pursuant to Clause 41 of the Listing Agreement.

7] Previous year's figures have been regrouped and rearranged wherever necessary.

For TWILIGHT LITAKA PHARMA LIMITED

TWILIGHT LITAKA PHARMA LTD. MUMBAI 72.

GOPAL RAMOURTI
Managing Director

Place : Mumbai
Date : 14/2/2013